Accel-Heal Solo
Accel-Heal is an electrical stimulation device that provides targeted therapy for hard-to-heal and painful wounds, including leg ulcers, diabetic foot ulcers and pressure ulcers.
It delivers an automatic, pulsed electrical stimulation during the 12-day treatment programme. The pulses are below the threshold for sensory stimulation which means that patients should not typically feel them yet they are strong enough to trigger the cellular responses needed to begin the healing process.
A pocket-sized device, Accel-Heal is discreet and does not hinder the patient’s mobility. The device is easily changed every 48-hours with no need to disrupt wound dressings and no need to replace the electrodes on the skin. The therapy can, therefore, be managed by the patient themselves or their carer in the comfort of their own home.
Select:
INNOVATIVE ELECTRICAL STIMULATION FOR HARD-TO-HEAL WOUNDS
Accel-Heal® relieves pain and stimulates healing by delivering a preset, automated programme of subsensory electrical pulses to the wound during a 12-day treatment course.
A single-use, portable, easy-to-use device, Accel-Heal® is ideal for independent use by the patient in their own home together with their standard therapy.
It is clinically proven to promote and stimulate healing and improve patient quality of life.
How to Apply
The 12-day treatment period begins by simply applying two electrode pads to the skin near the wound. During the 12 day treatment period the Accel-Heal device is changed for a new device. The electrode pads should be applied to intact skin on either side of the wound, then connected to the Accel-Heal device.
Once the dressing has been applied and the device switched on, electrical stimulation is delivered to the wound automatically with no further intervention required by the patient for 48 hours after application.
After 12 days, the device will automatically turn itself off. The electrodes should be replaced as necessary during the course of therapy.
Accel-Heal is an electrical stimulation device that provides targeted therapy for hard-to-heal and painful wounds, including leg ulcers, diabetic foot ulcers and pressure ulcers.
The electrical pulses generated by the Accel-Heal device are subsensory which means that they would not normally be felt. You may, however, experience a slight tingling sensation. This is normal and not a cause for concern. You should not experience any pain or discomfort during Accel-Heal therapy. In the unlikely event that you do, the device should be switched off and the electrode pads removed immediately.
In a hard-to-heal wound, electrical stimulation can trigger the cellular processes needed to kick-start wound healing.
FASTER HEALING
- More than 80 per cent of non-healing wounds healed within 20 weeks
- In wounds that were treated with Accel-Heal, the mean area of the wounds that healed was nearly twice as large (1.7-times) as in a placebo group
RELIEVES PAIN
- 87% reduction in pain during the 12-day treatment period
- Some patients reported pain reduction within hours of application
IMPROVED QUALITY OF LIFE
- Patients able to return to normal social activities thanks to experiencing less pain and increased mobility
- After being treated with Accel-Heal, some patients were able to go back to work.
COST EFFECTIVE
- Reduces the per-patient cost of managing a venous ulcer by up to £936 per annum
- A reduction in cost to the NHS by 11% for treatment of venous leg ulcers.
- Reduces the costs of dressing changes by up to a third
- Reduces the number of nursing visits needed per patient per year by 17 – 34%
Accel-Heal Solo is contraindicated for use in patients with active cancer, including any risk of malignancy in the wound. Patients with pacemakers should consult their medical practitioner and the device should not be placed near the chest wall. Do not use near the head for patients with epilepsy. As a precaution, due to lack of evidence, patients who are pregnant or under 18 should consult their medical practitioner. Do not place the electrode pads over broken capillaries, varicose veins, or main arteries.
The European Wound Management Association (EWMA) has acknowledged that electrical stimulation is effective in treating a wide range of wound types including venous leg ulcers, diabetic foot ulcers, pressure ulcers and mixed ulcers.
Evidence supporting electrical stimulation for wound healing
Many studies have investigated the use of electrical stimulation in wounds and the evidence base in this area is strong with five meta-analyses, six systematic reviews and over 30 RCTs reporting the benefits of the therapy (the diagram demonstrates evidence for electrical stimulation). Electrical stimulation is proven to improve healing whilst reducing pain and inflammation. Specific subsensory stimulation from devices such as Accel-Heal is safe to use.
Clinical Outcomes:
23 published articles, including 10 papers and 13 posters, describe the effects of Accel-Heal. These articles describe the results of 160 patients treated with Accel-Heal published in the clinical literature.
Venous Leg Ulcers
DFU
Vascular Ulcer
Others
Published Accel-Heal Mode of Action
Accel-Heal Solo
Accel-Heal is an electrical stimulation device that provides targeted therapy for hard-to-heal and painful wounds, including leg ulcers, diabetic foot ulcers and pressure ulcers.
It delivers an automatic, pulsed electrical stimulation during the 12-day treatment programme. The pulses are below the threshold for sensory stimulation which means that patients should not typically feel them yet they are strong enough to trigger the cellular responses needed to begin the healing process.
A pocket-sized device, Accel-Heal is discreet and does not hinder the patient’s mobility. The device is easily changed every 48-hours with no need to disrupt wound dressings and no need to replace the electrodes on the skin. The therapy can, therefore, be managed by the patient themselves or their carer in the comfort of their own home.
12-day therapyContact Us
Accel-Heal is an electrical stimulation device that provides targeted therapy for hard-to-heal and painful wounds, including leg ulcers, diabetic foot ulcers and pressure ulcers.
The electrical pulses generated by the Accel-Heal device are subsensory which means that they would not normally be felt. You may, however, experience a slight tingling sensation. This is normal and not a cause for concern. You should not experience any pain or discomfort during Accel-Heal therapy. In the unlikely event that you do, the device should be switched off and the electrode pads removed immediately.
In a hard-to-heal wound, electrical stimulation can trigger the cellular processes needed to kick-start wound healing.
FASTER HEALING
- More than 80 per cent of non-healing wounds healed within 20 weeks
- In wounds that were treated with Accel-Heal, the mean area of the wounds that healed was nearly twice as large (1.7-times) as in a placebo group
RELIEVES PAIN
- 87% reduction in pain during the 12-day treatment period
- Some patients reported pain reduction within hours of application
IMPROVED QUALITY OF LIFE
- Patients able to return to normal social activities thanks to experiencing less pain and increased mobility
- After being treated with Accel-Heal, some patients were able to go back to work.
COST EFFECTIVE
- Reduces the per-patient cost of managing a venous ulcer by upto £936 per annum
- A reduction in cost to the NHS by 11% for treatment of venous leg ulcers.
- Reduces the costs of dressing changes by up to a third
- Reduces the number of nursing visits needed per patient per year by 17 – 34%
INNOVATIVE ELECTRICAL STIMULATION FOR HARD-TO-HEAL WOUNDS
Accel-Heal® relieves pain and stimulates healing by delivering a preset, automated programme of subsensory electrical pulses to the wound during a 12-day treatment course.
A single-use, portable, easy-to-use device, Accel-Heal® is ideal for independent use by the patient in their own home together with their standard therapy.
It is clinically proven to promote and stimulate healing and improve patient quality of life.
How to Apply
The 12-day treatment period begins by simply applying two electrode pads to the skin near the wound. During the 12 day treatment period the Accel-Heal device is changed for a new device. The electrode pads should be applied to intact skin on either side of the wound, then connected to the Accel-Heal device.
Once the dressing has been applied and the device switched on, electrical stimulation is delivered to the wound automatically with no further intervention required by the patient for 48 hours after application.
After 12 days, the device will automatically turn itself off. The electrodes should be replaced as necessary during the course of therapy.
Accel-Heal Solo is contraindicated for use in patients with active cancer, including any risk of malignancy in the wound. Patients with pacemakers should consult their medical practitioner and the device should not be placed near the chest wall. Do not use near the head for patients with epilepsy. As a precaution, due to lack of evidence, patients who are pregnant or under 18 should consult their medical practitioner. Do not place the electrode pads over broken capillaries, varicose veins, or main arteries.
The European Wound Management Association (EWMA) has acknowledged that electrical stimulation is effective in treating a wide range of wound types including venous leg ulcers, diabetic foot ulcers, pressure ulcers and mixed ulcers.
Evidence supporting electrical stimulation for wound healing
Many studies have investigated the use of electrical stimulation in wounds and the evidence base in this area is strong with five meta-analyses, six systematic reviews and over 30 RCTs reporting the benefits of the therapy (the diagram demonstrates evidence for electrical stimulation). Electrical stimulation is proven to improve healing whilst reducing pain and inflammation. Specific subsensory stimulation from devices such as Accel-Heal is safe to use.
Clinical Outcomes:
23 published articles, including 10 papers and 13 posters, describe the effects of Accel-Heal. These articles describe the results of 160 patients treated with Accel-Heal published in the clinical literature.